GPCM
IMNM icon

Granite Point Capital Management’s Immunome IMNM Stock Holding History

Granite Point Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-66,666
Closed -$645K – 192
2020
Q4 		$645K Buy
+66,666
New +$778K 0.03% 133

Other funds holding IMNM

AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIM
Baldwin Investment Management West Conshohocken, Pennsylvania $856M AUM 9.05% 1-Year Est. Return

Granite Point Capital Management's IMNM Position: Q1 2021 in Review

Granite Point Capital Management sold out of Immunome (IMNM) in Q1 2021, closing a stake of 66,666 shares — an estimated $645K sold.

Granite Point Capital Management first reported a position in IMNM in Q4 2020 and held it in 1 quarter. The position peaked at $645K in Q4 2020. 31 funds tracked by Wall St. Rank hold IMNM as of Q1 2021.

  • Granite Point Capital Management reported no remaining Immunome position as of Q1 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 66,666 Immunome shares in Q1 2021, an estimated $645K.
  • Granite Point Capital Management first reported a position in Immunome in Q4 2020 and held it in 1 quarter.
  • Granite Point Capital Management's Immunome position peaked at $645K in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Immunome as of Q1 2021.

Based on Granite Point Capital Management's 13F filing for Q1 2021, filed 12 May 2021.